| Phase 18 trials |
|
Phase 1
|
NCT07570017 |
May 2026 → Dec 2027 expected |
diffuse large B-cell lymphoma |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07374224 |
Mar → Jun 2026 overdue |
— |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06251180 |
Apr 2024 → Dec 2025 overdue |
B-cell non-Hodgkin lymphoma |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06126861 |
Dec 2023 → Feb 2024 |
— |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05917964 |
Jun → Aug 2023 |
mantle cell lymphoma |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05432713 |
May → Nov 2022 |
multiple sclerosis, neuromyelitis optica |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04775745 |
Jul 2021 → Dec 2027 expected |
Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +3 |
Newave Pharmaceutical Inc |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04993690 |
Jul 2021 → Dec 2026 expected |
B-cell non-Hodgkin lymphoma |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Recruiting
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT07609862 |
May 2026 → Jun 2029 expected |
Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +1 |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Not yet recruiting
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT07189065 |
Nov 2025 → Dec 2027 expected |
diffuse large B-cell lymphoma |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06978088 |
Jun 2025 → Jun 2029 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Zulfa Omer |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05716087 |
Feb 2023 → Dec 2024 overdue |
mantle cell lymphoma |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Active not recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07342478 |
Apr 2026 → Oct 2029 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Newave Pharmaceutical Inc |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07377578 |
Feb 2026 → May 2031 expected |
mantle cell lymphoma |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Recruiting
|
No outcome recorded
|